首页> 外国专利> 2 - piridona Derivatives, method for their preparation, Pharmaceutical compositions containing them, a process for preparing the same and their use in the manufacture of medicaments for the treatment of diseases mediated by the activity of Neutrophil Elastase (HNE).

2 - piridona Derivatives, method for their preparation, Pharmaceutical compositions containing them, a process for preparing the same and their use in the manufacture of medicaments for the treatment of diseases mediated by the activity of Neutrophil Elastase (HNE).

机译:2-piridona衍生物,其制备方法,包含它们的药物组合物,其制备方法及其在制备用于治疗由中性粒细胞弹性蛋白酶(HNE)活性介导的疾病的药物中的用途。

摘要

Its preparation process, which includes the composition, processing method and use in treatment. These compounds are factors that inhibit the elasticity of neutron ofilos and are used to develop drugs for the treatment of HNE mediated diseases. Item 1: a compound whose characteristic is the response formula (1), wherein R1 represents h or C1-6 tar; W represents s (o) m, where M represents 0, 1 or 2 integer; Z represents a simple link, ch2-o-n25;R14 represents an H or H atom or a group selected between C1-6 tar and a saturated or unsaturated ring system composed of 3 to 10 members, wherein each group can optionally be replaced by at least one heteroatom in the ring selected between N and s, and each group can optionally be replaced by at least one alternative selected from phenyl, C1-6, halocarbon, C1-4, acoxy C1-4, acoxy C1-4, CN, oh, NO2, c1-3 tar is replaced by one or more F atoms, and Alcoy c1-3 is replaced by one or more F atoms, nr122r13, C: cr30, conr31r32, CHO, alkane c2-4, alkane (o) pr33 and os2r34; R12 and R13 represent independent h, C1-6, ilo-6;O group 12 R13 is added together to represent periodic rings of 5 to 7 members, optionally including an additional heteroatom between O, s, and nr26; R30 represents h, c1-3 tar, if (CH3) 3 or phenyl; R33 and R34 represent independent h or c1-3 tar; such tar is replaced by one or more atoms. F. R6 stands for H or F; R3 stands for phenyl or 5 or 6-member heteroaromatic ring, which contains 1 to 3 heteroatoms independently selected from O, s and N; the ring can be selectively replaced by at least one selected halogenated, C1-6 tar, cyanogen, alcox C1-6, nitrate, methyl carbon substitute,Nr35r36, c1-3 tar, replaced by one or more f or alcoxi c1-3 atoms, replaced by one or more F atoms; R35 and R36 independently represent h or c1-3 tar; such tar can also be replaced by one or more F atoms optionally; R4 stands for optional h or C1-6 tar, replaced by at least one selected alternative between F, hydroxy and alcoxi C1-6; x stands for a simple connection, or Nr24 or C1-6 tar-y -,It contains a simple link, O atom, Nr24 or s (o) W, and can be optionally replaced by Oh, halogeno, CN, nr37r38, alcox c1-3, conr39r40, so2r41 and so2nr42r43; The combination of O R4 and X makes - nr4x form a periodic ring with 5 to 7 members, optionally including an additional heteroatom between O, s and nr44; optionally replacing the ring with C1-6 or nr4546 tar; optionally replacing the ring with Oh tar; O R5 represents a selected monocyclic system between monophenyl (I) diphenyl (II) phenyl;iii) a 5-6 membered heteroaromatic ring comprising at least one heteroatom in the ring selected from N, O and S; iv) a partially unsaturated saturated C3-6 hydrocarbyl ring, or v) a 4- or 7-membered saturated or partially unsaturated heterocyclic ring comprising at least one heteroatom in the ring selected from O, S (O) and NR20, where at least a C atom in the ring may optionally be replaced by a carbonyl group, or R5 represents a bicyclic ring system where the two rings are independently selected from the monocyclic ring systems defined in ii),Three,iv) and v) above, where the two rings are either fused together,linked together or separated from each other by a binder group selected from O, S (O) to C1-6 alkylene optionally comprising one or more internal or terminal heteroatoms selected from O, S and NR27 and which are optionally substituted by at least one substituent selected from hydroxy, oxo and C1-6 alkoxy, the monocyclic or bicyclic ring system that are optionally substituted by at least one substituent selected from O, CN, OH, C1-6 alkyl, C1-6 alkoxy, halogen, NR47R48, NO2, OSO2R49, CO2R50, C (= NH) NH2, C (O) NR51R52, C (S) NR53R54, SC (= NH) NH2, NR55C (= NH) NH2, S (O) vR21, SO2NR56R57,C1-3 alkoxy substituted with one or more F atoms and C1-3 alkyl substituted with SO2R5 or with no or more F atoms; said C1-6 alkyl being also optionally substituted with at least one substituent selected from cyano, hydroxyl, C1-6 alkoxy, C1-6 alkylthio and -C (O) NR22R23; or R5 can also represent H; R20 represents H, C1-6 alkyl, C1-6 alkylcarbonyl or C1-6 alkoxycarbonyl; R21 represents H, C1-6 alkyl or C3-8 cycloalkyl, said alkyl or cycloalkyl group being also optionally substituted with one or more substituents independently selected from OH, CN, C1-3 alkoxy and CONR59R60; R37 and R38 independently represent H, C1-6 alkyl,C2-6 formyl or alkanoyl; R47 and R48 independently represent H, C1-6 alkyl, formyl, C2-6 alkanoyl, S (O) qR61 or SO2NR62R63; said alkyl group being optionally also substituted by halogen, CN, C1-4 alkoxy or CONR64R65; R41 and R61 independently represent H C1-6 alkyl or C3-6 cycloalkyl; p is 0, 1 or 2; q is 0, 1 or 2; r is 0, 1 or 2; t is 0, 1 or 2; w is 0, 1 or 2; v is 0, 1 or 2; R22, R23, R24, R25, R26, R27, R31, R32, R39, R40, R42, R43, R44, R45, R46, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R62, R63, R64 and R65 each independently represents H or C1-6 alkyl;Or an acceptable salt Item 8: a process for preparing a formula compound (1) or a second acceptable salt is defined in Article 1, which is characterized by (a) reacting a formula compound (2), wherein L1 represents a discrete group (such as hydrogen halide) and R1, R3, R6, R14, W and Z have the values defined in the formula (1),A compound containing formula (3), where x, R4, and R5 have values defined in formula (1),Or (b) when w represents s-and Z represents a simple o-ch2 link,reacting a compound of the formula (4) wherein Hal represents a halogen atom and X, R1, R3, R4, R5 and R6 have the values defined in the formula (1),R14-z-m containing r14-z-s-m nucleic acid, wherein R14 and Z have the values defined in formula (1), while M represents an organic boric acid container or organic substance, or (c) when w represents - s-and Z represents a simple o-ch2 link,A formula compound (4) is reacted, wherein "Hal" represents a halogenated atom, while x, 1, R3, 4, R5 and R6 have values (1) defined in the formula,1.1. Tiol r14-z-s-h, where R14 and Z have the values defined in the formula in the case of copper salt (1);O (d) when w represents s - and Z represents a simple o-ch2 link, a compound of formula (5) is reacted, wherein X, R1, R3, R4, R5 and R6 have the values defined in formula (1),Using r14-z-l2 electrolyte, L2 represents a group of discrete substances such as halides, R14 and Z, with the values defined in the formula (1),(e) When it stands for - SO2 and Z stands for - nr25,A formula compound (6) is reacted, wherein X, R1, R3, R4, R5 and R6 have values (1) defined in the formula,1. Amine containing r14-nhr25, wherein R14 and R25 have the values defined in formula (1),O (f) when w represents sulfur (- S (o -) or a group of (- S (o) 2 -) sulfur, the corresponding compound is oxidized, and W represents an uncle (- S -);Select next (a)(b)(c)(d)(e) Or (f) driving one or more of the following compounds: converting the obtained compound into another compound of the compound; forming an acceptable salt for the pharmaceutical use of the compound.
机译:其制备过程包括组成,加工方法和在治疗中的用途。这些化合物是抑制中子纤维弹性的因素,并用于开发用于治疗HNE介导的疾病的药物。第1项:特征在于响应式(1)的化合物,其中R 1表示h或C 1-6焦油; W代表s(o)m,其中M代表0、1或2的整数; Z代表一个简单的连接,ch2-o-n25; R14代表一个H或H原子或一个选自C1-6焦油和3至10个成员的饱和或不饱和环系的基团,其中每个基团可任选被取代环中至少一个在N和s之间选择的杂原子,并且每个基团可以任选地被选自苯基,C1-6,卤代烃,C1-4,酰氧基C1-4,酰氧基C1-4,CN中的至少一种取代基取代。 ,哦,NO2,c1-3焦油被一个或多个F原子取代,而醇c1-3被一个或多个F原子取代,nr122r13,C:cr30,conr31r32,CHO,烷烃c2-4,烷烃(o )pr33和os2r34; R 12和R 13代表独立的h,C 1-6,ilo-6; O基团12 R13加在一起代表5至7个成员的周期环,可选地在O,s和nr26之间包括一个额外的杂原子; R 30代表h,c 1-3焦油,如果(CH 3)3或苯基; R33和R34代表独立的h或c1-3焦油;这种焦油被一个或多个原子取代。 F. R6代表H或F; R3代表苯基或5或6元杂芳族环,其含有1-3个独立地选自O,s和N的杂原子;该环可被至少一个选定的卤代,C1-6焦油,氰,Alcox C1-6,硝酸盐,甲基碳取代基,Nr35r36,c1-3焦油选择性取代,并被一个或多个f或alcoxi c1-3原子取代,被一个或多个F原子取代; R35和R36独立地代表h或c1-3焦油;该焦油也可以任选地被一个或多个F原子取代; R4代表任选的h或C1-6焦油,被在F,羟基和醇C1-6之间的至少一个选择的替代物取代; x表示简单连接,或Nr24或C1-6 tar-y-,它包含一个简单的链接,O原子,Nr24或s(o)W,并且可以选择替换为Oh,卤代,CN,nr37r38,alcox c1-3,conr39r40,so2r41和so2nr42r43; O R4和X的组合使-nr4x形成​​具有5至7个成员的周期环,可选地在O,s和nr44之间包括一个额外的杂原子;可选用C1-6或nr4546焦油替换环;可以选择用Oh tar代替戒指; O R5代表单苯基(I)二苯基(II)苯基之间的选定的单环系统; iii)5-6元杂芳族环,该环中的至少一个杂原子选自N,O和S; iv)部分不饱和的饱和C 3-6烃基环,或v)4或7元饱和或部分不饱和的杂环,其在环中包含至少一个选自O,S(O)和NR 20的杂原子,其中至少所述环中的C原子可任选地被羰基取代,或R 5代表双环系统,其中两个环独立地选自以上ii),3,iv)和v)中定义的单环系统,其中两个环稠合在一起,连接在一起或通过选自O,S(O)至C1-6亚烷基的粘合剂基团彼此分开,所述粘合剂基团任选包含一个或多个选自O,S和NR27的内部或末端杂原子,且任选被至少一个选自羟基,氧代和C 1-6烷氧基的取代基取代的单环或双环体系,任选被至少一个选自O,CN,OH,C 1-6烷基,C 1-6烷氧基的取代基取代,卤素,NR47R48,NO2,OSO2R49,CO2R 50,C(= NH)NH2,C(O)NR51R52,C(S)NR53R54,SC(= NH)NH2,NR55C(= NH)NH2,S(O)vR21,SO2NR56R57,C1-3烷氧基被一个取代或更多的F原子和被SO 2 R 5取代或没有或没有更多的F原子的C 1-3烷基;所述C 1-6烷基还任选被至少一种选自氰基,羟基,C 1-6烷氧基,C 1-6烷硫基和-C(O)NR 22 R 23的取代基取代;或者R5也可以代表H; R 20代表H,C 1-6烷基,C 1-6烷基羰基或C 1-6烷氧羰基; R21代表H,C1-6烷基或C3-8环烷基,所述烷基或环烷基还任选地被一个或多个独立地选自OH,CN,C1-3烷氧基和CONR59R60的取代基取代; R37和R38独立地代表H,C1-6烷基,C2-6甲酰基或烷酰基; R47和R48独立地代表H,C1-6烷基,甲酰基,C2-6烷酰基,S(O)qR61或SO2NR62R63;所述烷基任选地还被卤素,CN,C1-4烷氧基或CONR64R65取代; R41和R61独立地代表H C1-6烷基或C3-6环烷基; p是0、1或2; q是0、1或2; r是0、1或2; t是0、1或2; w是0、1或2; v是0、1或2; R22,R23,R24,R25,R26,R27,R31,R32,R39,R40,R42,R43,R44,R45,R46,R49,R50,R51,R52,R53,R54,R55,R56,R57,R58, R59,R60,R62,R63,R 64和R 65各自独立地表示H或C 1-6烷基;或可接受的盐第8项:第1条定义了一种制备式化合物(1)或第二可接受的盐的方法,其特征在于(a)反应式(2)的化合物,其中L 1代表离散基团(例如卤化氢),并且R 1,R 3,R 6,R 14,W和Z具有式(1)中定义的值,包含式(3)的化合物,其中x,R4和R5具有式(1)中定义的值,或(b),当w表示s-且Z表示简单的o-ch2键时,与式(4)的化合物反应,其中Hal表示卤原子X,R1,R3,R4,R5和R6具有式(1)中定义的值,R14-zm包含r14-zsm核酸,其中R14和Z具有式(1)中定义的值,而M表示有机硼酸容器或有机物质,或(c)当w代表-s-且Z代表简单的o-ch2连接时,式化合物(4)反应,其中“ Hal”代表卤素原子,而x,1,R3、4,R5和R6具有式1.1定义的值(1)。 Tiol r14-zsh,其中R14和Z在铜盐(1)的情况下具有上式定义的值;当w表示s-且Z表示简单的o-ch2键时,O(d)为下式化合物: 5)反应,其中X,R1,R3,R4,R5和R6具有式(1)中定义的值,使用r14-z-l2电解质,L2代表一组离散物质,例如卤化物,R14和Z,具有式(1),(e)中定义的值时,当-代表SO2,Z代表-nr25时,式(6)反应,其中X,R1,R3,R4,R5和R6具有(1)在公式中定义1。当w代表硫(-S(o-)或一组(-S(o)2-)硫)时,含r14-nhr25的胺,其中R14和R25具有式(1)的定义,O(f),相应的化合物被氧化,W代表一个叔叔(-S-);选择下一个(a)(b)(c)(d)(e)或(f)驱动以下一种或多种化合物:化合物形成化合物的另一种化合物;形成可接受的盐以用于该化合物的药学用途。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号